phone iconPhone: (401) 822-4673
phone iconFax: (401) 822-4676
Receive our Health e-Newsletter

News for Healthier Living

New Regimen Protects Against Cancer Relapse, Graft-Versus-Host Disease After Donor Stem Cell Transplant

Results of a phase 1 clinical trial show that patients who undergo a blood stem cell transplant involving a donor have a lower risk of relapse and lower rates of graft-versus-host disease when they receive the targeted therapy VIC-1911 along with the standard-of-care regimen that includes post-transplant cyclophosphamide and sirolimus.

March 20, 2026


March 20 2026

March 19 2026

March 18 2026

March 17 2026

March 16 2026

March 15 2026

March 14 2026

March 13 2026

March 12 2026

March 11 2026

March 10 2026

March 9 2026

March 8 2026

March 7 2026

Angell Street Psychiatry
Copyright 2026 HealthBanks, Inc. All rights reserved.
Terms of Use | Privacy Policy